Global PD-1 and PD-L1 Monoclonal Antibodies Market Growth (Status and Outlook) 2026-2032
The global PD-1 and PD-L1 Monoclonal Antibodies market size is predicted to grow from US$ 1598 million in 2025 to US$ 2668 million in 2032; it is expected to grow at a CAGR of 8.0% from 2026 to 2032.
PD-1 and PD-L1 monoclonal antibodies are a class of immune checkpoint inhibitors that activate the body's own T cells to kill tumor cells by blocking the signaling pathways of programmed cell death protein 1 (PD-1) or its ligand (PD-L1); they have become standard therapies for various solid tumors and hematological malignancies. In 2025, global sales volume reached approximately 3.8 million vials, with an average price of about $430 per vial based on standard treatment regimens—a figure reflecting global price disparities and the impact of biosimilars—while capacity utilization stood at approximately 83%. Upstream players include culture media manufacturers such as Thermo Fisher and Merck; Protein A affinity chromatography resin suppliers like Cytiva and Nanomicro; and single-use bioreactor provider Sartorius. Downstream entities include hospital pharmacies, oncology clinics, and distributors such as McKesson and Shanghai Pharmaceuticals, with gross margins generally maintained at a high level of 88% to 92%. The product cost structure comprises direct raw materials (e.g., serum-free media, chromatography media, and buffers) at approximately 22%; fixed asset depreciation and cleanroom facilities at 18%; R&D amortization and registration expenses at 35%; and sales, administrative, and channel costs at 15%. Regarding demand and business opportunities, downstream applications cover first-line and adjuvant indications such as non-small cell lung cancer, gastric cancer, hepatocellular carcinoma, Hodgkin lymphoma, bladder cancer, esophageal cancer, and head and neck squamous cell carcinoma; key downstream clients include MD Anderson Cancer Center, Peking Union Medical College Hospital, Sinopharm Group, and Ali Health. Policy drivers include the inclusion of more PD-1 drugs in standard reimbursement lists following Chinese medical insurance negotiations and accelerated review pathways by global regulatory agencies. Technological innovation is evident in subcutaneous formulations, bispecific antibodies (e.g., PD-1/VEGF), and novel therapies combining PD-1 inhibitors with antibody-drug conjugates (ADCs). Finally, shifting consumer demands—with patients seeking longer survival, less frequent infusions, and reduced side effects like hair loss—are fueling interest in the development of long-acting injectables and oral formulations.
The PD-1 and PD-L1 monoclonal antibody market has transitioned from a phase of unchecked expansion to one of maturity and differentiation; while sales volumes continue to rise rapidly, prices are steadily declining due to biosimilars and national reimbursement negotiations, reflecting a strategy of trading price for volume. In the Chinese market, four domestic PD-1 products—from Junshi Biosciences, Innovent Biologics, BeiGene, and Hengrui Medicine—command over 70% of the market share, while imported drugs Keytruda (K-drug) and Opdivo (O-drug) maintain a high-end market stronghold by expanding into indications for early-stage cancer. The average unit price has dropped from tens of thousands of dollars in 2019 to the current national reimbursement price of approximately 3,000 RMB, and the global average price has fallen to $430 due to biosimilar penetration in India and Southeast Asia. A race to expand production capacity has left some companies with utilization rates of only 60%, whereas firms possessing high-expression cell lines and single-use bioreactor technologies maintain utilization rates exceeding 85% alongside lower costs. Future commercial opportunities lie in combination therapies and perioperative treatments; combinations involving PD-1 with chemotherapy, TIGIT, LAG-3, or ADCs are pushing new indications into the first-line setting, thereby extending treatment duration and expanding the patient base. Subcutaneous formulations, which reduce administration time to five minutes and significantly improve patient compliance, are emerging as a key tool for differentiation. On the policy front, the inclusion of early cancer screening in China’s "Healthy China 2030" agenda and the adoption of value-based (efficacy-linked) payment models in Europe and the US are driving higher penetration rates for PD-1 drugs. Furthermore, the expansion of indications into early-stage neoadjuvant and adjuvant settings has significantly lengthened treatment cycles for patients with resectable tumors, offsetting the impact of declining unit prices. Global PD-1 and PD-L1 usage is projected to exceed 1 billion patient-treatments by 2028; however, due to competition from biosimilars, sales revenue may see only modest growth, compelling innovative companies to rely on overseas expansion and combination patent strategies to sustain profitability.
This Insight Report provides a comprehensive analysis of the global PD-1 and PD-L1 Monoclonal Antibodies landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on PD-1 and PD-L1 Monoclonal Antibodies portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global PD-1 and PD-L1 Monoclonal Antibodies market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for PD-1 and PD-L1 Monoclonal Antibodies and breaks down the forecast by Target, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global PD-1 and PD-L1 Monoclonal Antibodies.
This report presents a comprehensive overview, market shares, and growth opportunities of PD-1 and PD-L1 Monoclonal Antibodies market by product type, application, key players and key regions and countries.
PD-1 and PD-L1 monoclonal antibodies are a class of immune checkpoint inhibitors that activate the body's own T cells to kill tumor cells by blocking the signaling pathways of programmed cell death protein 1 (PD-1) or its ligand (PD-L1); they have become standard therapies for various solid tumors and hematological malignancies. In 2025, global sales volume reached approximately 3.8 million vials, with an average price of about $430 per vial based on standard treatment regimens—a figure reflecting global price disparities and the impact of biosimilars—while capacity utilization stood at approximately 83%. Upstream players include culture media manufacturers such as Thermo Fisher and Merck; Protein A affinity chromatography resin suppliers like Cytiva and Nanomicro; and single-use bioreactor provider Sartorius. Downstream entities include hospital pharmacies, oncology clinics, and distributors such as McKesson and Shanghai Pharmaceuticals, with gross margins generally maintained at a high level of 88% to 92%. The product cost structure comprises direct raw materials (e.g., serum-free media, chromatography media, and buffers) at approximately 22%; fixed asset depreciation and cleanroom facilities at 18%; R&D amortization and registration expenses at 35%; and sales, administrative, and channel costs at 15%. Regarding demand and business opportunities, downstream applications cover first-line and adjuvant indications such as non-small cell lung cancer, gastric cancer, hepatocellular carcinoma, Hodgkin lymphoma, bladder cancer, esophageal cancer, and head and neck squamous cell carcinoma; key downstream clients include MD Anderson Cancer Center, Peking Union Medical College Hospital, Sinopharm Group, and Ali Health. Policy drivers include the inclusion of more PD-1 drugs in standard reimbursement lists following Chinese medical insurance negotiations and accelerated review pathways by global regulatory agencies. Technological innovation is evident in subcutaneous formulations, bispecific antibodies (e.g., PD-1/VEGF), and novel therapies combining PD-1 inhibitors with antibody-drug conjugates (ADCs). Finally, shifting consumer demands—with patients seeking longer survival, less frequent infusions, and reduced side effects like hair loss—are fueling interest in the development of long-acting injectables and oral formulations.
The PD-1 and PD-L1 monoclonal antibody market has transitioned from a phase of unchecked expansion to one of maturity and differentiation; while sales volumes continue to rise rapidly, prices are steadily declining due to biosimilars and national reimbursement negotiations, reflecting a strategy of trading price for volume. In the Chinese market, four domestic PD-1 products—from Junshi Biosciences, Innovent Biologics, BeiGene, and Hengrui Medicine—command over 70% of the market share, while imported drugs Keytruda (K-drug) and Opdivo (O-drug) maintain a high-end market stronghold by expanding into indications for early-stage cancer. The average unit price has dropped from tens of thousands of dollars in 2019 to the current national reimbursement price of approximately 3,000 RMB, and the global average price has fallen to $430 due to biosimilar penetration in India and Southeast Asia. A race to expand production capacity has left some companies with utilization rates of only 60%, whereas firms possessing high-expression cell lines and single-use bioreactor technologies maintain utilization rates exceeding 85% alongside lower costs. Future commercial opportunities lie in combination therapies and perioperative treatments; combinations involving PD-1 with chemotherapy, TIGIT, LAG-3, or ADCs are pushing new indications into the first-line setting, thereby extending treatment duration and expanding the patient base. Subcutaneous formulations, which reduce administration time to five minutes and significantly improve patient compliance, are emerging as a key tool for differentiation. On the policy front, the inclusion of early cancer screening in China’s "Healthy China 2030" agenda and the adoption of value-based (efficacy-linked) payment models in Europe and the US are driving higher penetration rates for PD-1 drugs. Furthermore, the expansion of indications into early-stage neoadjuvant and adjuvant settings has significantly lengthened treatment cycles for patients with resectable tumors, offsetting the impact of declining unit prices. Global PD-1 and PD-L1 usage is projected to exceed 1 billion patient-treatments by 2028; however, due to competition from biosimilars, sales revenue may see only modest growth, compelling innovative companies to rely on overseas expansion and combination patent strategies to sustain profitability.
Report Scope
LPI (LP Information)' newest research report, the “PD-1 and PD-L1 Monoclonal Antibodies Industry Forecast” looks at past sales and reviews total world PD-1 and PD-L1 Monoclonal Antibodies sales in 2025, providing a comprehensive analysis by region and market sector of projected PD-1 and PD-L1 Monoclonal Antibodies sales for 2026 through 2032. With PD-1 and PD-L1 Monoclonal Antibodies sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world PD-1 and PD-L1 Monoclonal Antibodies industry.This Insight Report provides a comprehensive analysis of the global PD-1 and PD-L1 Monoclonal Antibodies landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on PD-1 and PD-L1 Monoclonal Antibodies portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global PD-1 and PD-L1 Monoclonal Antibodies market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for PD-1 and PD-L1 Monoclonal Antibodies and breaks down the forecast by Target, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global PD-1 and PD-L1 Monoclonal Antibodies.
This report presents a comprehensive overview, market shares, and growth opportunities of PD-1 and PD-L1 Monoclonal Antibodies market by product type, application, key players and key regions and countries.
Market Segmentation
Segmentation by Target:
- PD-1 Monoclonal Antibody
- PD-L1 Monoclonal Antibody
Segmentation by Antibody Origin:
- Fully Human
- Humanized
Segmentation by Dosing Interval:
- Every 2 Weeks (Q2W)
- Every 3 Weeks (Q3W)
- Every 4 Weeks or Longer (?Q4W)
Segmentation by Application:
- Lung Cancer Treatment
- Melanoma Treatment
- Bowel Cancer Treatment
- Other
This report also splits the market by region:
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Merck & Co., Inc. (US)
- Bristol Myers Squibb Company (US)
- F. Hoffmann-La Roche Ltd (CH)
- Merck KGaA (DE)
- AstraZeneca plc (GB)
- Regeneron Pharmaceuticals, Inc. (US)
- GSK plc (GB)
- Incyte Corporation (US)
- BIOCAD JSC (RU)
- BeOne Medicines Ltd. (CH)
- Jiangsu Hengrui Pharmaceuticals Co., Ltd. (CN)
- Innovent Biologics, Inc. (CN)
- Shanghai Junshi Biosciences Co., Ltd. (CN)
- Shanghai Henlius Biotech, Inc. (CN)
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global PD-1 and PD-L1 Monoclonal Antibodies Market Size (2021-2032)
2.1.2 PD-1 and PD-L1 Monoclonal Antibodies Market Size CAGR by Region (2021 VS 2025 VS 2032)
2.1.3 World Current & Future Analysis for PD-1 and PD-L1 Monoclonal Antibodies by Country/Region (2021, 2025 & 2032)
2.2 PD-1 and PD-L1 Monoclonal Antibodies Segment by Target
2.2.1 PD-1 Monoclonal Antibody
2.2.2 PD-L1 Monoclonal Antibody
2.2.3 PD-1 and PD-L1 Monoclonal Antibodies Market Size by Target
2.2.3.1 PD-1 and PD-L1 Monoclonal Antibodies Market Size CAGR by Target (2021 VS 2025 VS 2032)
2.2.3.2 Global PD-1 and PD-L1 Monoclonal Antibodies Market Size Market Share by Target (2021-2026)
2.3 PD-1 and PD-L1 Monoclonal Antibodies Segment by Antibody Origin
2.3.1 Fully Human
2.3.2 Humanized
2.3.3 PD-1 and PD-L1 Monoclonal Antibodies Market Size by Antibody Origin
2.3.3.1 PD-1 and PD-L1 Monoclonal Antibodies Market Size CAGR by Antibody Origin (2021 VS 2025 VS 2032)
2.3.3.2 Global PD-1 and PD-L1 Monoclonal Antibodies Market Size Market Share by Antibody Origin (2021-2026)
2.4 PD-1 and PD-L1 Monoclonal Antibodies Segment by Dosing Interval
2.4.1 Every 2 Weeks (Q2W)
2.4.2 Every 3 Weeks (Q3W)
2.4.3 Every 4 Weeks or Longer (?Q4W)
2.4.4 PD-1 and PD-L1 Monoclonal Antibodies Market Size by Dosing Interval
2.4.4.1 PD-1 and PD-L1 Monoclonal Antibodies Market Size CAGR by Dosing Interval (2021 VS 2025 VS 2032)
2.4.4.2 Global PD-1 and PD-L1 Monoclonal Antibodies Market Size Market Share by Dosing Interval (2021-2026)
2.5 PD-1 and PD-L1 Monoclonal Antibodies Segment by Application
2.5.1 Lung Cancer Treatment
2.5.2 Melanoma Treatment
2.5.3 Bowel Cancer Treatment
2.5.4 Other
2.5.5 PD-1 and PD-L1 Monoclonal Antibodies Market Size by Application
2.5.5.1 PD-1 and PD-L1 Monoclonal Antibodies Market Size CAGR by Application (2021 VS 2025 VS 2032)
2.5.5.2 Global PD-1 and PD-L1 Monoclonal Antibodies Market Size Market Share by Application (2021-2026)
3 PD-1 AND PD-L1 MONOCLONAL ANTIBODIES MARKET SIZE BY PLAYER
3.1 PD-1 and PD-L1 Monoclonal Antibodies Market Size Market Share by Player
3.1.1 Global PD-1 and PD-L1 Monoclonal Antibodies Revenue by Player (2021-2026)
3.1.2 Global PD-1 and PD-L1 Monoclonal Antibodies Revenue Market Share by Player (2021-2026)
3.2 Global PD-1 and PD-L1 Monoclonal Antibodies Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 PD-1 AND PD-L1 MONOCLONAL ANTIBODIES BY REGION
4.1 PD-1 and PD-L1 Monoclonal Antibodies Market Size by Region (2021-2026)
4.2 Global PD-1 and PD-L1 Monoclonal Antibodies Annual Revenue by Country/Region (2021-2026)
4.3 Americas PD-1 and PD-L1 Monoclonal Antibodies Market Size Growth (2021-2026)
4.4 APAC PD-1 and PD-L1 Monoclonal Antibodies Market Size Growth (2021-2026)
4.5 Europe PD-1 and PD-L1 Monoclonal Antibodies Market Size Growth (2021-2026)
4.6 Middle East & Africa PD-1 and PD-L1 Monoclonal Antibodies Market Size Growth (2021-2026)
5 AMERICAS
5.1 Americas PD-1 and PD-L1 Monoclonal Antibodies Market Size by Country (2021-2026)
5.2 Americas PD-1 and PD-L1 Monoclonal Antibodies Market Size by Target (2021-2026)
5.3 Americas PD-1 and PD-L1 Monoclonal Antibodies Market Size by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC PD-1 and PD-L1 Monoclonal Antibodies Market Size by Region (2021-2026)
6.2 APAC PD-1 and PD-L1 Monoclonal Antibodies Market Size by Target (2021-2026)
6.3 APAC PD-1 and PD-L1 Monoclonal Antibodies Market Size by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 EUROPE
7.1 Europe PD-1 and PD-L1 Monoclonal Antibodies Market Size by Country (2021-2026)
7.2 Europe PD-1 and PD-L1 Monoclonal Antibodies Market Size by Target (2021-2026)
7.3 Europe PD-1 and PD-L1 Monoclonal Antibodies Market Size by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa PD-1 and PD-L1 Monoclonal Antibodies by Region (2021-2026)
8.2 Middle East & Africa PD-1 and PD-L1 Monoclonal Antibodies Market Size by Target (2021-2026)
8.3 Middle East & Africa PD-1 and PD-L1 Monoclonal Antibodies Market Size by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 GLOBAL PD-1 AND PD-L1 MONOCLONAL ANTIBODIES MARKET FORECAST
10.1 Global PD-1 and PD-L1 Monoclonal Antibodies Forecast by Region (2027-2032)
10.1.1 Global PD-1 and PD-L1 Monoclonal Antibodies Forecast by Region (2027-2032)
10.1.2 Americas PD-1 and PD-L1 Monoclonal Antibodies Forecast
10.1.3 APAC PD-1 and PD-L1 Monoclonal Antibodies Forecast
10.1.4 Europe PD-1 and PD-L1 Monoclonal Antibodies Forecast
10.1.5 Middle East & Africa PD-1 and PD-L1 Monoclonal Antibodies Forecast
10.2 Americas PD-1 and PD-L1 Monoclonal Antibodies Forecast by Country (2027-2032)
10.2.1 United States Market PD-1 and PD-L1 Monoclonal Antibodies Forecast
10.2.2 Canada Market PD-1 and PD-L1 Monoclonal Antibodies Forecast
10.2.3 Mexico Market PD-1 and PD-L1 Monoclonal Antibodies Forecast
10.2.4 Brazil Market PD-1 and PD-L1 Monoclonal Antibodies Forecast
10.3 APAC PD-1 and PD-L1 Monoclonal Antibodies Forecast by Region (2027-2032)
10.3.1 China PD-1 and PD-L1 Monoclonal Antibodies Market Forecast
10.3.2 Japan Market PD-1 and PD-L1 Monoclonal Antibodies Forecast
10.3.3 Korea Market PD-1 and PD-L1 Monoclonal Antibodies Forecast
10.3.4 Southeast Asia Market PD-1 and PD-L1 Monoclonal Antibodies Forecast
10.3.5 India Market PD-1 and PD-L1 Monoclonal Antibodies Forecast
10.3.6 Australia Market PD-1 and PD-L1 Monoclonal Antibodies Forecast
10.4 Europe PD-1 and PD-L1 Monoclonal Antibodies Forecast by Country (2027-2032)
10.4.1 Germany Market PD-1 and PD-L1 Monoclonal Antibodies Forecast
10.4.2 France Market PD-1 and PD-L1 Monoclonal Antibodies Forecast
10.4.3 UK Market PD-1 and PD-L1 Monoclonal Antibodies Forecast
10.4.4 Italy Market PD-1 and PD-L1 Monoclonal Antibodies Forecast
10.4.5 Russia Market PD-1 and PD-L1 Monoclonal Antibodies Forecast
10.5 Middle East & Africa PD-1 and PD-L1 Monoclonal Antibodies Forecast by Region (2027-2032)
10.5.1 Egypt Market PD-1 and PD-L1 Monoclonal Antibodies Forecast
10.5.2 South Africa Market PD-1 and PD-L1 Monoclonal Antibodies Forecast
10.5.3 Israel Market PD-1 and PD-L1 Monoclonal Antibodies Forecast
10.5.4 Turkey Market PD-1 and PD-L1 Monoclonal Antibodies Forecast
10.6 Global PD-1 and PD-L1 Monoclonal Antibodies Forecast by Target (2027-2032)
10.7 Global PD-1 and PD-L1 Monoclonal Antibodies Forecast by Application (2027-2032)
10.7.1 GCC Countries Market PD-1 and PD-L1 Monoclonal Antibodies Forecast
11 KEY PLAYERS ANALYSIS
11.1 Merck & Co., Inc. (US)
11.1.1 Merck & Co., Inc. (US) Company Information
11.1.2 Merck & Co., Inc. (US) PD-1 and PD-L1 Monoclonal Antibodies Product Offered
11.1.3 Merck & Co., Inc. (US) PD-1 and PD-L1 Monoclonal Antibodies Revenue, Gross Margin and Market Share (2021-2026)
11.1.4 Merck & Co., Inc. (US) Main Business Overview
11.1.5 Merck & Co., Inc. (US) Latest Developments
11.2 Bristol Myers Squibb Company (US)
11.2.1 Bristol Myers Squibb Company (US) Company Information
11.2.2 Bristol Myers Squibb Company (US) PD-1 and PD-L1 Monoclonal Antibodies Product Offered
11.2.3 Bristol Myers Squibb Company (US) PD-1 and PD-L1 Monoclonal Antibodies Revenue, Gross Margin and Market Share (2021-2026)
11.2.4 Bristol Myers Squibb Company (US) Main Business Overview
11.2.5 Bristol Myers Squibb Company (US) Latest Developments
11.3 F. Hoffmann-La Roche Ltd (CH)
11.3.1 F. Hoffmann-La Roche Ltd (CH) Company Information
11.3.2 F. Hoffmann-La Roche Ltd (CH) PD-1 and PD-L1 Monoclonal Antibodies Product Offered
11.3.3 F. Hoffmann-La Roche Ltd (CH) PD-1 and PD-L1 Monoclonal Antibodies Revenue, Gross Margin and Market Share (2021-2026)
11.3.4 F. Hoffmann-La Roche Ltd (CH) Main Business Overview
11.3.5 F. Hoffmann-La Roche Ltd (CH) Latest Developments
11.4 Merck KGaA (DE)
11.4.1 Merck KGaA (DE) Company Information
11.4.2 Merck KGaA (DE) PD-1 and PD-L1 Monoclonal Antibodies Product Offered
11.4.3 Merck KGaA (DE) PD-1 and PD-L1 Monoclonal Antibodies Revenue, Gross Margin and Market Share (2021-2026)
11.4.4 Merck KGaA (DE) Main Business Overview
11.4.5 Merck KGaA (DE) Latest Developments
11.5 AstraZeneca plc (GB)
11.5.1 AstraZeneca plc (GB) Company Information
11.5.2 AstraZeneca plc (GB) PD-1 and PD-L1 Monoclonal Antibodies Product Offered
11.5.3 AstraZeneca plc (GB) PD-1 and PD-L1 Monoclonal Antibodies Revenue, Gross Margin and Market Share (2021-2026)
11.5.4 AstraZeneca plc (GB) Main Business Overview
11.5.5 AstraZeneca plc (GB) Latest Developments
11.6 Regeneron Pharmaceuticals, Inc. (US)
11.6.1 Regeneron Pharmaceuticals, Inc. (US) Company Information
11.6.2 Regeneron Pharmaceuticals, Inc. (US) PD-1 and PD-L1 Monoclonal Antibodies Product Offered
11.6.3 Regeneron Pharmaceuticals, Inc. (US) PD-1 and PD-L1 Monoclonal Antibodies Revenue, Gross Margin and Market Share (2021-2026)
11.6.4 Regeneron Pharmaceuticals, Inc. (US) Main Business Overview
11.6.5 Regeneron Pharmaceuticals, Inc. (US) Latest Developments
11.7 GSK plc (GB)
11.7.1 GSK plc (GB) Company Information
11.7.2 GSK plc (GB) PD-1 and PD-L1 Monoclonal Antibodies Product Offered
11.7.3 GSK plc (GB) PD-1 and PD-L1 Monoclonal Antibodies Revenue, Gross Margin and Market Share (2021-2026)
11.7.4 GSK plc (GB) Main Business Overview
11.7.5 GSK plc (GB) Latest Developments
11.8 Incyte Corporation (US)
11.8.1 Incyte Corporation (US) Company Information
11.8.2 Incyte Corporation (US) PD-1 and PD-L1 Monoclonal Antibodies Product Offered
11.8.3 Incyte Corporation (US) PD-1 and PD-L1 Monoclonal Antibodies Revenue, Gross Margin and Market Share (2021-2026)
11.8.4 Incyte Corporation (US) Main Business Overview
11.8.5 Incyte Corporation (US) Latest Developments
11.9 BIOCAD JSC (RU)
11.9.1 BIOCAD JSC (RU) Company Information
11.9.2 BIOCAD JSC (RU) PD-1 and PD-L1 Monoclonal Antibodies Product Offered
11.9.3 BIOCAD JSC (RU) PD-1 and PD-L1 Monoclonal Antibodies Revenue, Gross Margin and Market Share (2021-2026)
11.9.4 BIOCAD JSC (RU) Main Business Overview
11.9.5 BIOCAD JSC (RU) Latest Developments
11.10 BeOne Medicines Ltd. (CH)
11.10.1 BeOne Medicines Ltd. (CH) Company Information
11.10.2 BeOne Medicines Ltd. (CH) PD-1 and PD-L1 Monoclonal Antibodies Product Offered
11.10.3 BeOne Medicines Ltd. (CH) PD-1 and PD-L1 Monoclonal Antibodies Revenue, Gross Margin and Market Share (2021-2026)
11.10.4 BeOne Medicines Ltd. (CH) Main Business Overview
11.10.5 BeOne Medicines Ltd. (CH) Latest Developments
11.11 Jiangsu Hengrui Pharmaceuticals Co., Ltd. (CN)
11.11.1 Jiangsu Hengrui Pharmaceuticals Co., Ltd. (CN) Company Information
11.11.2 Jiangsu Hengrui Pharmaceuticals Co., Ltd. (CN) PD-1 and PD-L1 Monoclonal Antibodies Product Offered
11.11.3 Jiangsu Hengrui Pharmaceuticals Co., Ltd. (CN) PD-1 and PD-L1 Monoclonal Antibodies Revenue, Gross Margin and Market Share (2021-2026)
11.11.4 Jiangsu Hengrui Pharmaceuticals Co., Ltd. (CN) Main Business Overview
11.11.5 Jiangsu Hengrui Pharmaceuticals Co., Ltd. (CN) Latest Developments
11.12 Innovent Biologics, Inc. (CN)
11.12.1 Innovent Biologics, Inc. (CN) Company Information
11.12.2 Innovent Biologics, Inc. (CN) PD-1 and PD-L1 Monoclonal Antibodies Product Offered
11.12.3 Innovent Biologics, Inc. (CN) PD-1 and PD-L1 Monoclonal Antibodies Revenue, Gross Margin and Market Share (2021-2026)
11.12.4 Innovent Biologics, Inc. (CN) Main Business Overview
11.12.5 Innovent Biologics, Inc. (CN) Latest Developments
11.13 Shanghai Junshi Biosciences Co., Ltd. (CN)
11.13.1 Shanghai Junshi Biosciences Co., Ltd. (CN) Company Information
11.13.2 Shanghai Junshi Biosciences Co., Ltd. (CN) PD-1 and PD-L1 Monoclonal Antibodies Product Offered
11.13.3 Shanghai Junshi Biosciences Co., Ltd. (CN) PD-1 and PD-L1 Monoclonal Antibodies Revenue, Gross Margin and Market Share (2021-2026)
11.13.4 Shanghai Junshi Biosciences Co., Ltd. (CN) Main Business Overview
11.13.5 Shanghai Junshi Biosciences Co., Ltd. (CN) Latest Developments
11.14 Shanghai Henlius Biotech, Inc. (CN)
11.14.1 Shanghai Henlius Biotech, Inc. (CN) Company Information
11.14.2 Shanghai Henlius Biotech, Inc. (CN) PD-1 and PD-L1 Monoclonal Antibodies Product Offered
11.14.3 Shanghai Henlius Biotech, Inc. (CN) PD-1 and PD-L1 Monoclonal Antibodies Revenue, Gross Margin and Market Share (2021-2026)
11.14.4 Shanghai Henlius Biotech, Inc. (CN) Main Business Overview
11.14.5 Shanghai Henlius Biotech, Inc. (CN) Latest Developments
12 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global PD-1 and PD-L1 Monoclonal Antibodies Market Size (2021-2032)
2.1.2 PD-1 and PD-L1 Monoclonal Antibodies Market Size CAGR by Region (2021 VS 2025 VS 2032)
2.1.3 World Current & Future Analysis for PD-1 and PD-L1 Monoclonal Antibodies by Country/Region (2021, 2025 & 2032)
2.2 PD-1 and PD-L1 Monoclonal Antibodies Segment by Target
2.2.1 PD-1 Monoclonal Antibody
2.2.2 PD-L1 Monoclonal Antibody
2.2.3 PD-1 and PD-L1 Monoclonal Antibodies Market Size by Target
2.2.3.1 PD-1 and PD-L1 Monoclonal Antibodies Market Size CAGR by Target (2021 VS 2025 VS 2032)
2.2.3.2 Global PD-1 and PD-L1 Monoclonal Antibodies Market Size Market Share by Target (2021-2026)
2.3 PD-1 and PD-L1 Monoclonal Antibodies Segment by Antibody Origin
2.3.1 Fully Human
2.3.2 Humanized
2.3.3 PD-1 and PD-L1 Monoclonal Antibodies Market Size by Antibody Origin
2.3.3.1 PD-1 and PD-L1 Monoclonal Antibodies Market Size CAGR by Antibody Origin (2021 VS 2025 VS 2032)
2.3.3.2 Global PD-1 and PD-L1 Monoclonal Antibodies Market Size Market Share by Antibody Origin (2021-2026)
2.4 PD-1 and PD-L1 Monoclonal Antibodies Segment by Dosing Interval
2.4.1 Every 2 Weeks (Q2W)
2.4.2 Every 3 Weeks (Q3W)
2.4.3 Every 4 Weeks or Longer (?Q4W)
2.4.4 PD-1 and PD-L1 Monoclonal Antibodies Market Size by Dosing Interval
2.4.4.1 PD-1 and PD-L1 Monoclonal Antibodies Market Size CAGR by Dosing Interval (2021 VS 2025 VS 2032)
2.4.4.2 Global PD-1 and PD-L1 Monoclonal Antibodies Market Size Market Share by Dosing Interval (2021-2026)
2.5 PD-1 and PD-L1 Monoclonal Antibodies Segment by Application
2.5.1 Lung Cancer Treatment
2.5.2 Melanoma Treatment
2.5.3 Bowel Cancer Treatment
2.5.4 Other
2.5.5 PD-1 and PD-L1 Monoclonal Antibodies Market Size by Application
2.5.5.1 PD-1 and PD-L1 Monoclonal Antibodies Market Size CAGR by Application (2021 VS 2025 VS 2032)
2.5.5.2 Global PD-1 and PD-L1 Monoclonal Antibodies Market Size Market Share by Application (2021-2026)
3 PD-1 AND PD-L1 MONOCLONAL ANTIBODIES MARKET SIZE BY PLAYER
3.1 PD-1 and PD-L1 Monoclonal Antibodies Market Size Market Share by Player
3.1.1 Global PD-1 and PD-L1 Monoclonal Antibodies Revenue by Player (2021-2026)
3.1.2 Global PD-1 and PD-L1 Monoclonal Antibodies Revenue Market Share by Player (2021-2026)
3.2 Global PD-1 and PD-L1 Monoclonal Antibodies Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 PD-1 AND PD-L1 MONOCLONAL ANTIBODIES BY REGION
4.1 PD-1 and PD-L1 Monoclonal Antibodies Market Size by Region (2021-2026)
4.2 Global PD-1 and PD-L1 Monoclonal Antibodies Annual Revenue by Country/Region (2021-2026)
4.3 Americas PD-1 and PD-L1 Monoclonal Antibodies Market Size Growth (2021-2026)
4.4 APAC PD-1 and PD-L1 Monoclonal Antibodies Market Size Growth (2021-2026)
4.5 Europe PD-1 and PD-L1 Monoclonal Antibodies Market Size Growth (2021-2026)
4.6 Middle East & Africa PD-1 and PD-L1 Monoclonal Antibodies Market Size Growth (2021-2026)
5 AMERICAS
5.1 Americas PD-1 and PD-L1 Monoclonal Antibodies Market Size by Country (2021-2026)
5.2 Americas PD-1 and PD-L1 Monoclonal Antibodies Market Size by Target (2021-2026)
5.3 Americas PD-1 and PD-L1 Monoclonal Antibodies Market Size by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC PD-1 and PD-L1 Monoclonal Antibodies Market Size by Region (2021-2026)
6.2 APAC PD-1 and PD-L1 Monoclonal Antibodies Market Size by Target (2021-2026)
6.3 APAC PD-1 and PD-L1 Monoclonal Antibodies Market Size by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 EUROPE
7.1 Europe PD-1 and PD-L1 Monoclonal Antibodies Market Size by Country (2021-2026)
7.2 Europe PD-1 and PD-L1 Monoclonal Antibodies Market Size by Target (2021-2026)
7.3 Europe PD-1 and PD-L1 Monoclonal Antibodies Market Size by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa PD-1 and PD-L1 Monoclonal Antibodies by Region (2021-2026)
8.2 Middle East & Africa PD-1 and PD-L1 Monoclonal Antibodies Market Size by Target (2021-2026)
8.3 Middle East & Africa PD-1 and PD-L1 Monoclonal Antibodies Market Size by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 GLOBAL PD-1 AND PD-L1 MONOCLONAL ANTIBODIES MARKET FORECAST
10.1 Global PD-1 and PD-L1 Monoclonal Antibodies Forecast by Region (2027-2032)
10.1.1 Global PD-1 and PD-L1 Monoclonal Antibodies Forecast by Region (2027-2032)
10.1.2 Americas PD-1 and PD-L1 Monoclonal Antibodies Forecast
10.1.3 APAC PD-1 and PD-L1 Monoclonal Antibodies Forecast
10.1.4 Europe PD-1 and PD-L1 Monoclonal Antibodies Forecast
10.1.5 Middle East & Africa PD-1 and PD-L1 Monoclonal Antibodies Forecast
10.2 Americas PD-1 and PD-L1 Monoclonal Antibodies Forecast by Country (2027-2032)
10.2.1 United States Market PD-1 and PD-L1 Monoclonal Antibodies Forecast
10.2.2 Canada Market PD-1 and PD-L1 Monoclonal Antibodies Forecast
10.2.3 Mexico Market PD-1 and PD-L1 Monoclonal Antibodies Forecast
10.2.4 Brazil Market PD-1 and PD-L1 Monoclonal Antibodies Forecast
10.3 APAC PD-1 and PD-L1 Monoclonal Antibodies Forecast by Region (2027-2032)
10.3.1 China PD-1 and PD-L1 Monoclonal Antibodies Market Forecast
10.3.2 Japan Market PD-1 and PD-L1 Monoclonal Antibodies Forecast
10.3.3 Korea Market PD-1 and PD-L1 Monoclonal Antibodies Forecast
10.3.4 Southeast Asia Market PD-1 and PD-L1 Monoclonal Antibodies Forecast
10.3.5 India Market PD-1 and PD-L1 Monoclonal Antibodies Forecast
10.3.6 Australia Market PD-1 and PD-L1 Monoclonal Antibodies Forecast
10.4 Europe PD-1 and PD-L1 Monoclonal Antibodies Forecast by Country (2027-2032)
10.4.1 Germany Market PD-1 and PD-L1 Monoclonal Antibodies Forecast
10.4.2 France Market PD-1 and PD-L1 Monoclonal Antibodies Forecast
10.4.3 UK Market PD-1 and PD-L1 Monoclonal Antibodies Forecast
10.4.4 Italy Market PD-1 and PD-L1 Monoclonal Antibodies Forecast
10.4.5 Russia Market PD-1 and PD-L1 Monoclonal Antibodies Forecast
10.5 Middle East & Africa PD-1 and PD-L1 Monoclonal Antibodies Forecast by Region (2027-2032)
10.5.1 Egypt Market PD-1 and PD-L1 Monoclonal Antibodies Forecast
10.5.2 South Africa Market PD-1 and PD-L1 Monoclonal Antibodies Forecast
10.5.3 Israel Market PD-1 and PD-L1 Monoclonal Antibodies Forecast
10.5.4 Turkey Market PD-1 and PD-L1 Monoclonal Antibodies Forecast
10.6 Global PD-1 and PD-L1 Monoclonal Antibodies Forecast by Target (2027-2032)
10.7 Global PD-1 and PD-L1 Monoclonal Antibodies Forecast by Application (2027-2032)
10.7.1 GCC Countries Market PD-1 and PD-L1 Monoclonal Antibodies Forecast
11 KEY PLAYERS ANALYSIS
11.1 Merck & Co., Inc. (US)
11.1.1 Merck & Co., Inc. (US) Company Information
11.1.2 Merck & Co., Inc. (US) PD-1 and PD-L1 Monoclonal Antibodies Product Offered
11.1.3 Merck & Co., Inc. (US) PD-1 and PD-L1 Monoclonal Antibodies Revenue, Gross Margin and Market Share (2021-2026)
11.1.4 Merck & Co., Inc. (US) Main Business Overview
11.1.5 Merck & Co., Inc. (US) Latest Developments
11.2 Bristol Myers Squibb Company (US)
11.2.1 Bristol Myers Squibb Company (US) Company Information
11.2.2 Bristol Myers Squibb Company (US) PD-1 and PD-L1 Monoclonal Antibodies Product Offered
11.2.3 Bristol Myers Squibb Company (US) PD-1 and PD-L1 Monoclonal Antibodies Revenue, Gross Margin and Market Share (2021-2026)
11.2.4 Bristol Myers Squibb Company (US) Main Business Overview
11.2.5 Bristol Myers Squibb Company (US) Latest Developments
11.3 F. Hoffmann-La Roche Ltd (CH)
11.3.1 F. Hoffmann-La Roche Ltd (CH) Company Information
11.3.2 F. Hoffmann-La Roche Ltd (CH) PD-1 and PD-L1 Monoclonal Antibodies Product Offered
11.3.3 F. Hoffmann-La Roche Ltd (CH) PD-1 and PD-L1 Monoclonal Antibodies Revenue, Gross Margin and Market Share (2021-2026)
11.3.4 F. Hoffmann-La Roche Ltd (CH) Main Business Overview
11.3.5 F. Hoffmann-La Roche Ltd (CH) Latest Developments
11.4 Merck KGaA (DE)
11.4.1 Merck KGaA (DE) Company Information
11.4.2 Merck KGaA (DE) PD-1 and PD-L1 Monoclonal Antibodies Product Offered
11.4.3 Merck KGaA (DE) PD-1 and PD-L1 Monoclonal Antibodies Revenue, Gross Margin and Market Share (2021-2026)
11.4.4 Merck KGaA (DE) Main Business Overview
11.4.5 Merck KGaA (DE) Latest Developments
11.5 AstraZeneca plc (GB)
11.5.1 AstraZeneca plc (GB) Company Information
11.5.2 AstraZeneca plc (GB) PD-1 and PD-L1 Monoclonal Antibodies Product Offered
11.5.3 AstraZeneca plc (GB) PD-1 and PD-L1 Monoclonal Antibodies Revenue, Gross Margin and Market Share (2021-2026)
11.5.4 AstraZeneca plc (GB) Main Business Overview
11.5.5 AstraZeneca plc (GB) Latest Developments
11.6 Regeneron Pharmaceuticals, Inc. (US)
11.6.1 Regeneron Pharmaceuticals, Inc. (US) Company Information
11.6.2 Regeneron Pharmaceuticals, Inc. (US) PD-1 and PD-L1 Monoclonal Antibodies Product Offered
11.6.3 Regeneron Pharmaceuticals, Inc. (US) PD-1 and PD-L1 Monoclonal Antibodies Revenue, Gross Margin and Market Share (2021-2026)
11.6.4 Regeneron Pharmaceuticals, Inc. (US) Main Business Overview
11.6.5 Regeneron Pharmaceuticals, Inc. (US) Latest Developments
11.7 GSK plc (GB)
11.7.1 GSK plc (GB) Company Information
11.7.2 GSK plc (GB) PD-1 and PD-L1 Monoclonal Antibodies Product Offered
11.7.3 GSK plc (GB) PD-1 and PD-L1 Monoclonal Antibodies Revenue, Gross Margin and Market Share (2021-2026)
11.7.4 GSK plc (GB) Main Business Overview
11.7.5 GSK plc (GB) Latest Developments
11.8 Incyte Corporation (US)
11.8.1 Incyte Corporation (US) Company Information
11.8.2 Incyte Corporation (US) PD-1 and PD-L1 Monoclonal Antibodies Product Offered
11.8.3 Incyte Corporation (US) PD-1 and PD-L1 Monoclonal Antibodies Revenue, Gross Margin and Market Share (2021-2026)
11.8.4 Incyte Corporation (US) Main Business Overview
11.8.5 Incyte Corporation (US) Latest Developments
11.9 BIOCAD JSC (RU)
11.9.1 BIOCAD JSC (RU) Company Information
11.9.2 BIOCAD JSC (RU) PD-1 and PD-L1 Monoclonal Antibodies Product Offered
11.9.3 BIOCAD JSC (RU) PD-1 and PD-L1 Monoclonal Antibodies Revenue, Gross Margin and Market Share (2021-2026)
11.9.4 BIOCAD JSC (RU) Main Business Overview
11.9.5 BIOCAD JSC (RU) Latest Developments
11.10 BeOne Medicines Ltd. (CH)
11.10.1 BeOne Medicines Ltd. (CH) Company Information
11.10.2 BeOne Medicines Ltd. (CH) PD-1 and PD-L1 Monoclonal Antibodies Product Offered
11.10.3 BeOne Medicines Ltd. (CH) PD-1 and PD-L1 Monoclonal Antibodies Revenue, Gross Margin and Market Share (2021-2026)
11.10.4 BeOne Medicines Ltd. (CH) Main Business Overview
11.10.5 BeOne Medicines Ltd. (CH) Latest Developments
11.11 Jiangsu Hengrui Pharmaceuticals Co., Ltd. (CN)
11.11.1 Jiangsu Hengrui Pharmaceuticals Co., Ltd. (CN) Company Information
11.11.2 Jiangsu Hengrui Pharmaceuticals Co., Ltd. (CN) PD-1 and PD-L1 Monoclonal Antibodies Product Offered
11.11.3 Jiangsu Hengrui Pharmaceuticals Co., Ltd. (CN) PD-1 and PD-L1 Monoclonal Antibodies Revenue, Gross Margin and Market Share (2021-2026)
11.11.4 Jiangsu Hengrui Pharmaceuticals Co., Ltd. (CN) Main Business Overview
11.11.5 Jiangsu Hengrui Pharmaceuticals Co., Ltd. (CN) Latest Developments
11.12 Innovent Biologics, Inc. (CN)
11.12.1 Innovent Biologics, Inc. (CN) Company Information
11.12.2 Innovent Biologics, Inc. (CN) PD-1 and PD-L1 Monoclonal Antibodies Product Offered
11.12.3 Innovent Biologics, Inc. (CN) PD-1 and PD-L1 Monoclonal Antibodies Revenue, Gross Margin and Market Share (2021-2026)
11.12.4 Innovent Biologics, Inc. (CN) Main Business Overview
11.12.5 Innovent Biologics, Inc. (CN) Latest Developments
11.13 Shanghai Junshi Biosciences Co., Ltd. (CN)
11.13.1 Shanghai Junshi Biosciences Co., Ltd. (CN) Company Information
11.13.2 Shanghai Junshi Biosciences Co., Ltd. (CN) PD-1 and PD-L1 Monoclonal Antibodies Product Offered
11.13.3 Shanghai Junshi Biosciences Co., Ltd. (CN) PD-1 and PD-L1 Monoclonal Antibodies Revenue, Gross Margin and Market Share (2021-2026)
11.13.4 Shanghai Junshi Biosciences Co., Ltd. (CN) Main Business Overview
11.13.5 Shanghai Junshi Biosciences Co., Ltd. (CN) Latest Developments
11.14 Shanghai Henlius Biotech, Inc. (CN)
11.14.1 Shanghai Henlius Biotech, Inc. (CN) Company Information
11.14.2 Shanghai Henlius Biotech, Inc. (CN) PD-1 and PD-L1 Monoclonal Antibodies Product Offered
11.14.3 Shanghai Henlius Biotech, Inc. (CN) PD-1 and PD-L1 Monoclonal Antibodies Revenue, Gross Margin and Market Share (2021-2026)
11.14.4 Shanghai Henlius Biotech, Inc. (CN) Main Business Overview
11.14.5 Shanghai Henlius Biotech, Inc. (CN) Latest Developments
12 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. PD-1 and PD-L1 Monoclonal Antibodies Market Size CAGR by Region (2021 VS 2025 VS 2032) & ($ millions)
Table 2. PD-1 and PD-L1 Monoclonal Antibodies Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of PD-1 Monoclonal Antibody
Table 4. Major Players of PD-L1 Monoclonal Antibody
Table 5. PD-1 and PD-L1 Monoclonal Antibodies Market Size CAGR by Target (2021 VS 2025 VS 2032) & ($ millions)
Table 6. Global PD-1 and PD-L1 Monoclonal Antibodies Market Size by Target (2021-2026) & ($ millions)
Table 7. Global PD-1 and PD-L1 Monoclonal Antibodies Market Size Market Share by Target (2021-2026)
Table 8. Major Players of Fully Human
Table 9. Major Players of Humanized
Table 10. PD-1 and PD-L1 Monoclonal Antibodies Market Size CAGR by Antibody Origin (2021 VS 2025 VS 2032) & ($ millions)
Table 11. Global PD-1 and PD-L1 Monoclonal Antibodies Market Size by Antibody Origin (2021-2026) & ($ millions)
Table 12. Global PD-1 and PD-L1 Monoclonal Antibodies Market Size Market Share by Antibody Origin (2021-2026)
Table 13. Major Players of Every 2 Weeks (Q2W)
Table 14. Major Players of Every 3 Weeks (Q3W)
Table 15. Major Players of Every 4 Weeks or Longer (?Q4W)
Table 16. PD-1 and PD-L1 Monoclonal Antibodies Market Size CAGR by Dosing Interval (2021 VS 2025 VS 2032) & ($ millions)
Table 17. Global PD-1 and PD-L1 Monoclonal Antibodies Market Size by Dosing Interval (2021-2026) & ($ millions)
Table 18. Global PD-1 and PD-L1 Monoclonal Antibodies Market Size Market Share by Dosing Interval (2021-2026)
Table 19. PD-1 and PD-L1 Monoclonal Antibodies Market Size CAGR by Application (2021 VS 2025 VS 2032) & ($ millions)
Table 20. Global PD-1 and PD-L1 Monoclonal Antibodies Market Size by Application (2021-2026) & ($ millions)
Table 21. Global PD-1 and PD-L1 Monoclonal Antibodies Market Size Market Share by Application (2021-2026)
Table 22. Global PD-1 and PD-L1 Monoclonal Antibodies Revenue by Player (2021-2026) & ($ millions)
Table 23. Global PD-1 and PD-L1 Monoclonal Antibodies Revenue Market Share by Player (2021-2026)
Table 24. PD-1 and PD-L1 Monoclonal Antibodies Key Players Head office and Products Offered
Table 25. PD-1 and PD-L1 Monoclonal Antibodies Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 26. New Products and Potential Entrants
Table 27. Mergers & Acquisitions, Expansion
Table 28. Global PD-1 and PD-L1 Monoclonal Antibodies Market Size by Region (2021-2026) & ($ millions)
Table 29. Global PD-1 and PD-L1 Monoclonal Antibodies Market Size Market Share by Region (2021-2026)
Table 30. Global PD-1 and PD-L1 Monoclonal Antibodies Revenue by Country/Region (2021-2026) & ($ millions)
Table 31. Global PD-1 and PD-L1 Monoclonal Antibodies Revenue Market Share by Country/Region (2021-2026)
Table 32. Americas PD-1 and PD-L1 Monoclonal Antibodies Market Size by Country (2021-2026) & ($ millions)
Table 33. Americas PD-1 and PD-L1 Monoclonal Antibodies Market Size Market Share by Country (2021-2026)
Table 34. Americas PD-1 and PD-L1 Monoclonal Antibodies Market Size by Target (2021-2026) & ($ millions)
Table 35. Americas PD-1 and PD-L1 Monoclonal Antibodies Market Size Market Share by Target (2021-2026)
Table 36. Americas PD-1 and PD-L1 Monoclonal Antibodies Market Size by Application (2021-2026) & ($ millions)
Table 37. Americas PD-1 and PD-L1 Monoclonal Antibodies Market Size Market Share by Application (2021-2026)
Table 38. APAC PD-1 and PD-L1 Monoclonal Antibodies Market Size by Region (2021-2026) & ($ millions)
Table 39. APAC PD-1 and PD-L1 Monoclonal Antibodies Market Size Market Share by Region (2021-2026)
Table 40. APAC PD-1 and PD-L1 Monoclonal Antibodies Market Size by Target (2021-2026) & ($ millions)
Table 41. APAC PD-1 and PD-L1 Monoclonal Antibodies Market Size by Application (2021-2026) & ($ millions)
Table 42. Europe PD-1 and PD-L1 Monoclonal Antibodies Market Size by Country (2021-2026) & ($ millions)
Table 43. Europe PD-1 and PD-L1 Monoclonal Antibodies Market Size Market Share by Country (2021-2026)
Table 44. Europe PD-1 and PD-L1 Monoclonal Antibodies Market Size by Target (2021-2026) & ($ millions)
Table 45. Europe PD-1 and PD-L1 Monoclonal Antibodies Market Size by Application (2021-2026) & ($ millions)
Table 46. Middle East & Africa PD-1 and PD-L1 Monoclonal Antibodies Market Size by Region (2021-2026) & ($ millions)
Table 47. Middle East & Africa PD-1 and PD-L1 Monoclonal Antibodies Market Size by Target (2021-2026) & ($ millions)
Table 48. Middle East & Africa PD-1 and PD-L1 Monoclonal Antibodies Market Size by Application (2021-2026) & ($ millions)
Table 49. Key Market Drivers & Growth Opportunities of PD-1 and PD-L1 Monoclonal Antibodies
Table 50. Key Market Challenges & Risks of PD-1 and PD-L1 Monoclonal Antibodies
Table 51. Key Industry Trends of PD-1 and PD-L1 Monoclonal Antibodies
Table 52. Global PD-1 and PD-L1 Monoclonal Antibodies Market Size Forecast by Region (2027-2032) & ($ millions)
Table 53. Global PD-1 and PD-L1 Monoclonal Antibodies Market Size Market Share Forecast by Region (2027-2032)
Table 54. Global PD-1 and PD-L1 Monoclonal Antibodies Market Size Forecast by Target (2027-2032) & ($ millions)
Table 55. Global PD-1 and PD-L1 Monoclonal Antibodies Market Size Forecast by Application (2027-2032) & ($ millions)
Table 56. Merck & Co., Inc. (US) Details, Company Type, PD-1 and PD-L1 Monoclonal Antibodies Area Served and Its Competitors
Table 57. Merck & Co., Inc. (US) PD-1 and PD-L1 Monoclonal Antibodies Product Offered
Table 58. Merck & Co., Inc. (US) PD-1 and PD-L1 Monoclonal Antibodies Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 59. Merck & Co., Inc. (US) Main Business
Table 60. Merck & Co., Inc. (US) Latest Developments
Table 61. Bristol Myers Squibb Company (US) Details, Company Type, PD-1 and PD-L1 Monoclonal Antibodies Area Served and Its Competitors
Table 62. Bristol Myers Squibb Company (US) PD-1 and PD-L1 Monoclonal Antibodies Product Offered
Table 63. Bristol Myers Squibb Company (US) PD-1 and PD-L1 Monoclonal Antibodies Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 64. Bristol Myers Squibb Company (US) Main Business
Table 65. Bristol Myers Squibb Company (US) Latest Developments
Table 66. F. Hoffmann-La Roche Ltd (CH) Details, Company Type, PD-1 and PD-L1 Monoclonal Antibodies Area Served and Its Competitors
Table 67. F. Hoffmann-La Roche Ltd (CH) PD-1 and PD-L1 Monoclonal Antibodies Product Offered
Table 68. F. Hoffmann-La Roche Ltd (CH) PD-1 and PD-L1 Monoclonal Antibodies Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 69. F. Hoffmann-La Roche Ltd (CH) Main Business
Table 70. F. Hoffmann-La Roche Ltd (CH) Latest Developments
Table 71. Merck KGaA (DE) Details, Company Type, PD-1 and PD-L1 Monoclonal Antibodies Area Served and Its Competitors
Table 72. Merck KGaA (DE) PD-1 and PD-L1 Monoclonal Antibodies Product Offered
Table 73. Merck KGaA (DE) PD-1 and PD-L1 Monoclonal Antibodies Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 74. Merck KGaA (DE) Main Business
Table 75. Merck KGaA (DE) Latest Developments
Table 76. AstraZeneca plc (GB) Details, Company Type, PD-1 and PD-L1 Monoclonal Antibodies Area Served and Its Competitors
Table 77. AstraZeneca plc (GB) PD-1 and PD-L1 Monoclonal Antibodies Product Offered
Table 78. AstraZeneca plc (GB) PD-1 and PD-L1 Monoclonal Antibodies Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 79. AstraZeneca plc (GB) Main Business
Table 80. AstraZeneca plc (GB) Latest Developments
Table 81. Regeneron Pharmaceuticals, Inc. (US) Details, Company Type, PD-1 and PD-L1 Monoclonal Antibodies Area Served and Its Competitors
Table 82. Regeneron Pharmaceuticals, Inc. (US) PD-1 and PD-L1 Monoclonal Antibodies Product Offered
Table 83. Regeneron Pharmaceuticals, Inc. (US) PD-1 and PD-L1 Monoclonal Antibodies Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 84. Regeneron Pharmaceuticals, Inc. (US) Main Business
Table 85. Regeneron Pharmaceuticals, Inc. (US) Latest Developments
Table 86. GSK plc (GB) Details, Company Type, PD-1 and PD-L1 Monoclonal Antibodies Area Served and Its Competitors
Table 87. GSK plc (GB) PD-1 and PD-L1 Monoclonal Antibodies Product Offered
Table 88. GSK plc (GB) PD-1 and PD-L1 Monoclonal Antibodies Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 89. GSK plc (GB) Main Business
Table 90. GSK plc (GB) Latest Developments
Table 91. Incyte Corporation (US) Details, Company Type, PD-1 and PD-L1 Monoclonal Antibodies Area Served and Its Competitors
Table 92. Incyte Corporation (US) PD-1 and PD-L1 Monoclonal Antibodies Product Offered
Table 93. Incyte Corporation (US) PD-1 and PD-L1 Monoclonal Antibodies Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 94. Incyte Corporation (US) Main Business
Table 95. Incyte Corporation (US) Latest Developments
Table 96. BIOCAD JSC (RU) Details, Company Type, PD-1 and PD-L1 Monoclonal Antibodies Area Served and Its Competitors
Table 97. BIOCAD JSC (RU) PD-1 and PD-L1 Monoclonal Antibodies Product Offered
Table 98. BIOCAD JSC (RU) PD-1 and PD-L1 Monoclonal Antibodies Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 99. BIOCAD JSC (RU) Main Business
Table 100. BIOCAD JSC (RU) Latest Developments
Table 101. BeOne Medicines Ltd. (CH) Details, Company Type, PD-1 and PD-L1 Monoclonal Antibodies Area Served and Its Competitors
Table 102. BeOne Medicines Ltd. (CH) PD-1 and PD-L1 Monoclonal Antibodies Product Offered
Table 103. BeOne Medicines Ltd. (CH) PD-1 and PD-L1 Monoclonal Antibodies Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 104. BeOne Medicines Ltd. (CH) Main Business
Table 105. BeOne Medicines Ltd. (CH) Latest Developments
Table 106. Jiangsu Hengrui Pharmaceuticals Co., Ltd. (CN) Details, Company Type, PD-1 and PD-L1 Monoclonal Antibodies Area Served and Its Competitors
Table 107. Jiangsu Hengrui Pharmaceuticals Co., Ltd. (CN) PD-1 and PD-L1 Monoclonal Antibodies Product Offered
Table 108. Jiangsu Hengrui Pharmaceuticals Co., Ltd. (CN) PD-1 and PD-L1 Monoclonal Antibodies Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 109. Jiangsu Hengrui Pharmaceuticals Co., Ltd. (CN) Main Business
Table 110. Jiangsu Hengrui Pharmaceuticals Co., Ltd. (CN) Latest Developments
Table 111. Innovent Biologics, Inc. (CN) Details, Company Type, PD-1 and PD-L1 Monoclonal Antibodies Area Served and Its Competitors
Table 112. Innovent Biologics, Inc. (CN) PD-1 and PD-L1 Monoclonal Antibodies Product Offered
Table 113. Innovent Biologics, Inc. (CN) PD-1 and PD-L1 Monoclonal Antibodies Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 114. Innovent Biologics, Inc. (CN) Main Business
Table 115. Innovent Biologics, Inc. (CN) Latest Developments
Table 116. Shanghai Junshi Biosciences Co., Ltd. (CN) Details, Company Type, PD-1 and PD-L1 Monoclonal Antibodies Area Served and Its Competitors
Table 117. Shanghai Junshi Biosciences Co., Ltd. (CN) PD-1 and PD-L1 Monoclonal Antibodies Product Offered
Table 118. Shanghai Junshi Biosciences Co., Ltd. (CN) PD-1 and PD-L1 Monoclonal Antibodies Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 119. Shanghai Junshi Biosciences Co., Ltd. (CN) Main Business
Table 120. Shanghai Junshi Biosciences Co., Ltd. (CN) Latest Developments
Table 121. Shanghai Henlius Biotech, Inc. (CN) Details, Company Type, PD-1 and PD-L1 Monoclonal Antibodies Area Served and Its Competitors
Table 122. Shanghai Henlius Biotech, Inc. (CN) PD-1 and PD-L1 Monoclonal Antibodies Product Offered
Table 123. Shanghai Henlius Biotech, Inc. (CN) PD-1 and PD-L1 Monoclonal Antibodies Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 124. Shanghai Henlius Biotech, Inc. (CN) Main Business
Table 125. Shanghai Henlius Biotech, Inc. (CN) Latest Developments
Table 1. PD-1 and PD-L1 Monoclonal Antibodies Market Size CAGR by Region (2021 VS 2025 VS 2032) & ($ millions)
Table 2. PD-1 and PD-L1 Monoclonal Antibodies Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of PD-1 Monoclonal Antibody
Table 4. Major Players of PD-L1 Monoclonal Antibody
Table 5. PD-1 and PD-L1 Monoclonal Antibodies Market Size CAGR by Target (2021 VS 2025 VS 2032) & ($ millions)
Table 6. Global PD-1 and PD-L1 Monoclonal Antibodies Market Size by Target (2021-2026) & ($ millions)
Table 7. Global PD-1 and PD-L1 Monoclonal Antibodies Market Size Market Share by Target (2021-2026)
Table 8. Major Players of Fully Human
Table 9. Major Players of Humanized
Table 10. PD-1 and PD-L1 Monoclonal Antibodies Market Size CAGR by Antibody Origin (2021 VS 2025 VS 2032) & ($ millions)
Table 11. Global PD-1 and PD-L1 Monoclonal Antibodies Market Size by Antibody Origin (2021-2026) & ($ millions)
Table 12. Global PD-1 and PD-L1 Monoclonal Antibodies Market Size Market Share by Antibody Origin (2021-2026)
Table 13. Major Players of Every 2 Weeks (Q2W)
Table 14. Major Players of Every 3 Weeks (Q3W)
Table 15. Major Players of Every 4 Weeks or Longer (?Q4W)
Table 16. PD-1 and PD-L1 Monoclonal Antibodies Market Size CAGR by Dosing Interval (2021 VS 2025 VS 2032) & ($ millions)
Table 17. Global PD-1 and PD-L1 Monoclonal Antibodies Market Size by Dosing Interval (2021-2026) & ($ millions)
Table 18. Global PD-1 and PD-L1 Monoclonal Antibodies Market Size Market Share by Dosing Interval (2021-2026)
Table 19. PD-1 and PD-L1 Monoclonal Antibodies Market Size CAGR by Application (2021 VS 2025 VS 2032) & ($ millions)
Table 20. Global PD-1 and PD-L1 Monoclonal Antibodies Market Size by Application (2021-2026) & ($ millions)
Table 21. Global PD-1 and PD-L1 Monoclonal Antibodies Market Size Market Share by Application (2021-2026)
Table 22. Global PD-1 and PD-L1 Monoclonal Antibodies Revenue by Player (2021-2026) & ($ millions)
Table 23. Global PD-1 and PD-L1 Monoclonal Antibodies Revenue Market Share by Player (2021-2026)
Table 24. PD-1 and PD-L1 Monoclonal Antibodies Key Players Head office and Products Offered
Table 25. PD-1 and PD-L1 Monoclonal Antibodies Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 26. New Products and Potential Entrants
Table 27. Mergers & Acquisitions, Expansion
Table 28. Global PD-1 and PD-L1 Monoclonal Antibodies Market Size by Region (2021-2026) & ($ millions)
Table 29. Global PD-1 and PD-L1 Monoclonal Antibodies Market Size Market Share by Region (2021-2026)
Table 30. Global PD-1 and PD-L1 Monoclonal Antibodies Revenue by Country/Region (2021-2026) & ($ millions)
Table 31. Global PD-1 and PD-L1 Monoclonal Antibodies Revenue Market Share by Country/Region (2021-2026)
Table 32. Americas PD-1 and PD-L1 Monoclonal Antibodies Market Size by Country (2021-2026) & ($ millions)
Table 33. Americas PD-1 and PD-L1 Monoclonal Antibodies Market Size Market Share by Country (2021-2026)
Table 34. Americas PD-1 and PD-L1 Monoclonal Antibodies Market Size by Target (2021-2026) & ($ millions)
Table 35. Americas PD-1 and PD-L1 Monoclonal Antibodies Market Size Market Share by Target (2021-2026)
Table 36. Americas PD-1 and PD-L1 Monoclonal Antibodies Market Size by Application (2021-2026) & ($ millions)
Table 37. Americas PD-1 and PD-L1 Monoclonal Antibodies Market Size Market Share by Application (2021-2026)
Table 38. APAC PD-1 and PD-L1 Monoclonal Antibodies Market Size by Region (2021-2026) & ($ millions)
Table 39. APAC PD-1 and PD-L1 Monoclonal Antibodies Market Size Market Share by Region (2021-2026)
Table 40. APAC PD-1 and PD-L1 Monoclonal Antibodies Market Size by Target (2021-2026) & ($ millions)
Table 41. APAC PD-1 and PD-L1 Monoclonal Antibodies Market Size by Application (2021-2026) & ($ millions)
Table 42. Europe PD-1 and PD-L1 Monoclonal Antibodies Market Size by Country (2021-2026) & ($ millions)
Table 43. Europe PD-1 and PD-L1 Monoclonal Antibodies Market Size Market Share by Country (2021-2026)
Table 44. Europe PD-1 and PD-L1 Monoclonal Antibodies Market Size by Target (2021-2026) & ($ millions)
Table 45. Europe PD-1 and PD-L1 Monoclonal Antibodies Market Size by Application (2021-2026) & ($ millions)
Table 46. Middle East & Africa PD-1 and PD-L1 Monoclonal Antibodies Market Size by Region (2021-2026) & ($ millions)
Table 47. Middle East & Africa PD-1 and PD-L1 Monoclonal Antibodies Market Size by Target (2021-2026) & ($ millions)
Table 48. Middle East & Africa PD-1 and PD-L1 Monoclonal Antibodies Market Size by Application (2021-2026) & ($ millions)
Table 49. Key Market Drivers & Growth Opportunities of PD-1 and PD-L1 Monoclonal Antibodies
Table 50. Key Market Challenges & Risks of PD-1 and PD-L1 Monoclonal Antibodies
Table 51. Key Industry Trends of PD-1 and PD-L1 Monoclonal Antibodies
Table 52. Global PD-1 and PD-L1 Monoclonal Antibodies Market Size Forecast by Region (2027-2032) & ($ millions)
Table 53. Global PD-1 and PD-L1 Monoclonal Antibodies Market Size Market Share Forecast by Region (2027-2032)
Table 54. Global PD-1 and PD-L1 Monoclonal Antibodies Market Size Forecast by Target (2027-2032) & ($ millions)
Table 55. Global PD-1 and PD-L1 Monoclonal Antibodies Market Size Forecast by Application (2027-2032) & ($ millions)
Table 56. Merck & Co., Inc. (US) Details, Company Type, PD-1 and PD-L1 Monoclonal Antibodies Area Served and Its Competitors
Table 57. Merck & Co., Inc. (US) PD-1 and PD-L1 Monoclonal Antibodies Product Offered
Table 58. Merck & Co., Inc. (US) PD-1 and PD-L1 Monoclonal Antibodies Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 59. Merck & Co., Inc. (US) Main Business
Table 60. Merck & Co., Inc. (US) Latest Developments
Table 61. Bristol Myers Squibb Company (US) Details, Company Type, PD-1 and PD-L1 Monoclonal Antibodies Area Served and Its Competitors
Table 62. Bristol Myers Squibb Company (US) PD-1 and PD-L1 Monoclonal Antibodies Product Offered
Table 63. Bristol Myers Squibb Company (US) PD-1 and PD-L1 Monoclonal Antibodies Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 64. Bristol Myers Squibb Company (US) Main Business
Table 65. Bristol Myers Squibb Company (US) Latest Developments
Table 66. F. Hoffmann-La Roche Ltd (CH) Details, Company Type, PD-1 and PD-L1 Monoclonal Antibodies Area Served and Its Competitors
Table 67. F. Hoffmann-La Roche Ltd (CH) PD-1 and PD-L1 Monoclonal Antibodies Product Offered
Table 68. F. Hoffmann-La Roche Ltd (CH) PD-1 and PD-L1 Monoclonal Antibodies Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 69. F. Hoffmann-La Roche Ltd (CH) Main Business
Table 70. F. Hoffmann-La Roche Ltd (CH) Latest Developments
Table 71. Merck KGaA (DE) Details, Company Type, PD-1 and PD-L1 Monoclonal Antibodies Area Served and Its Competitors
Table 72. Merck KGaA (DE) PD-1 and PD-L1 Monoclonal Antibodies Product Offered
Table 73. Merck KGaA (DE) PD-1 and PD-L1 Monoclonal Antibodies Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 74. Merck KGaA (DE) Main Business
Table 75. Merck KGaA (DE) Latest Developments
Table 76. AstraZeneca plc (GB) Details, Company Type, PD-1 and PD-L1 Monoclonal Antibodies Area Served and Its Competitors
Table 77. AstraZeneca plc (GB) PD-1 and PD-L1 Monoclonal Antibodies Product Offered
Table 78. AstraZeneca plc (GB) PD-1 and PD-L1 Monoclonal Antibodies Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 79. AstraZeneca plc (GB) Main Business
Table 80. AstraZeneca plc (GB) Latest Developments
Table 81. Regeneron Pharmaceuticals, Inc. (US) Details, Company Type, PD-1 and PD-L1 Monoclonal Antibodies Area Served and Its Competitors
Table 82. Regeneron Pharmaceuticals, Inc. (US) PD-1 and PD-L1 Monoclonal Antibodies Product Offered
Table 83. Regeneron Pharmaceuticals, Inc. (US) PD-1 and PD-L1 Monoclonal Antibodies Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 84. Regeneron Pharmaceuticals, Inc. (US) Main Business
Table 85. Regeneron Pharmaceuticals, Inc. (US) Latest Developments
Table 86. GSK plc (GB) Details, Company Type, PD-1 and PD-L1 Monoclonal Antibodies Area Served and Its Competitors
Table 87. GSK plc (GB) PD-1 and PD-L1 Monoclonal Antibodies Product Offered
Table 88. GSK plc (GB) PD-1 and PD-L1 Monoclonal Antibodies Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 89. GSK plc (GB) Main Business
Table 90. GSK plc (GB) Latest Developments
Table 91. Incyte Corporation (US) Details, Company Type, PD-1 and PD-L1 Monoclonal Antibodies Area Served and Its Competitors
Table 92. Incyte Corporation (US) PD-1 and PD-L1 Monoclonal Antibodies Product Offered
Table 93. Incyte Corporation (US) PD-1 and PD-L1 Monoclonal Antibodies Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 94. Incyte Corporation (US) Main Business
Table 95. Incyte Corporation (US) Latest Developments
Table 96. BIOCAD JSC (RU) Details, Company Type, PD-1 and PD-L1 Monoclonal Antibodies Area Served and Its Competitors
Table 97. BIOCAD JSC (RU) PD-1 and PD-L1 Monoclonal Antibodies Product Offered
Table 98. BIOCAD JSC (RU) PD-1 and PD-L1 Monoclonal Antibodies Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 99. BIOCAD JSC (RU) Main Business
Table 100. BIOCAD JSC (RU) Latest Developments
Table 101. BeOne Medicines Ltd. (CH) Details, Company Type, PD-1 and PD-L1 Monoclonal Antibodies Area Served and Its Competitors
Table 102. BeOne Medicines Ltd. (CH) PD-1 and PD-L1 Monoclonal Antibodies Product Offered
Table 103. BeOne Medicines Ltd. (CH) PD-1 and PD-L1 Monoclonal Antibodies Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 104. BeOne Medicines Ltd. (CH) Main Business
Table 105. BeOne Medicines Ltd. (CH) Latest Developments
Table 106. Jiangsu Hengrui Pharmaceuticals Co., Ltd. (CN) Details, Company Type, PD-1 and PD-L1 Monoclonal Antibodies Area Served and Its Competitors
Table 107. Jiangsu Hengrui Pharmaceuticals Co., Ltd. (CN) PD-1 and PD-L1 Monoclonal Antibodies Product Offered
Table 108. Jiangsu Hengrui Pharmaceuticals Co., Ltd. (CN) PD-1 and PD-L1 Monoclonal Antibodies Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 109. Jiangsu Hengrui Pharmaceuticals Co., Ltd. (CN) Main Business
Table 110. Jiangsu Hengrui Pharmaceuticals Co., Ltd. (CN) Latest Developments
Table 111. Innovent Biologics, Inc. (CN) Details, Company Type, PD-1 and PD-L1 Monoclonal Antibodies Area Served and Its Competitors
Table 112. Innovent Biologics, Inc. (CN) PD-1 and PD-L1 Monoclonal Antibodies Product Offered
Table 113. Innovent Biologics, Inc. (CN) PD-1 and PD-L1 Monoclonal Antibodies Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 114. Innovent Biologics, Inc. (CN) Main Business
Table 115. Innovent Biologics, Inc. (CN) Latest Developments
Table 116. Shanghai Junshi Biosciences Co., Ltd. (CN) Details, Company Type, PD-1 and PD-L1 Monoclonal Antibodies Area Served and Its Competitors
Table 117. Shanghai Junshi Biosciences Co., Ltd. (CN) PD-1 and PD-L1 Monoclonal Antibodies Product Offered
Table 118. Shanghai Junshi Biosciences Co., Ltd. (CN) PD-1 and PD-L1 Monoclonal Antibodies Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 119. Shanghai Junshi Biosciences Co., Ltd. (CN) Main Business
Table 120. Shanghai Junshi Biosciences Co., Ltd. (CN) Latest Developments
Table 121. Shanghai Henlius Biotech, Inc. (CN) Details, Company Type, PD-1 and PD-L1 Monoclonal Antibodies Area Served and Its Competitors
Table 122. Shanghai Henlius Biotech, Inc. (CN) PD-1 and PD-L1 Monoclonal Antibodies Product Offered
Table 123. Shanghai Henlius Biotech, Inc. (CN) PD-1 and PD-L1 Monoclonal Antibodies Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 124. Shanghai Henlius Biotech, Inc. (CN) Main Business
Table 125. Shanghai Henlius Biotech, Inc. (CN) Latest Developments
LIST OF FIGURES
Figure 1. PD-1 and PD-L1 Monoclonal Antibodies Report Years Considered
Figure 2. Research Objectives
Figure 3. Research Methodology
Figure 4. Research Process and Data Source
Figure 5. Global PD-1 and PD-L1 Monoclonal Antibodies Market Size Growth Rate (2021-2032) ($ millions)
Figure 6. PD-1 and PD-L1 Monoclonal Antibodies Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 7. PD-1 and PD-L1 Monoclonal Antibodies Sales Market Share by Country/Region (2025)
Figure 8. PD-1 and PD-L1 Monoclonal Antibodies Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 9. Global PD-1 and PD-L1 Monoclonal Antibodies Market Size Market Share by Target in 2025
Figure 10. Global PD-1 and PD-L1 Monoclonal Antibodies Market Size Market Share by Antibody Origin in 2025
Figure 11. Global PD-1 and PD-L1 Monoclonal Antibodies Market Size Market Share by Dosing Interval in 2025
Figure 12. PD-1 and PD-L1 Monoclonal Antibodies in Lung Cancer Treatment
Figure 13. Global PD-1 and PD-L1 Monoclonal Antibodies Market: Lung Cancer Treatment (2021-2026) & ($ millions)
Figure 14. PD-1 and PD-L1 Monoclonal Antibodies in Melanoma Treatment
Figure 15. Global PD-1 and PD-L1 Monoclonal Antibodies Market: Melanoma Treatment (2021-2026) & ($ millions)
Figure 16. PD-1 and PD-L1 Monoclonal Antibodies in Bowel Cancer Treatment
Figure 17. Global PD-1 and PD-L1 Monoclonal Antibodies Market: Bowel Cancer Treatment (2021-2026) & ($ millions)
Figure 18. PD-1 and PD-L1 Monoclonal Antibodies in Other
Figure 19. Global PD-1 and PD-L1 Monoclonal Antibodies Market: Other (2021-2026) & ($ millions)
Figure 20. Global PD-1 and PD-L1 Monoclonal Antibodies Market Size Market Share by Application in 2025
Figure 21. Global PD-1 and PD-L1 Monoclonal Antibodies Revenue Market Share by Player in 2025
Figure 22. Global PD-1 and PD-L1 Monoclonal Antibodies Market Size Market Share by Region (2021-2026)
Figure 23. Americas PD-1 and PD-L1 Monoclonal Antibodies Market Size 2021-2026 ($ millions)
Figure 24. APAC PD-1 and PD-L1 Monoclonal Antibodies Market Size 2021-2026 ($ millions)
Figure 25. Europe PD-1 and PD-L1 Monoclonal Antibodies Market Size 2021-2026 ($ millions)
Figure 26. Middle East & Africa PD-1 and PD-L1 Monoclonal Antibodies Market Size 2021-2026 ($ millions)
Figure 27. Americas PD-1 and PD-L1 Monoclonal Antibodies Value Market Share by Country in 2025
Figure 28. United States PD-1 and PD-L1 Monoclonal Antibodies Market Size Growth 2021-2026 ($ millions)
Figure 29. Canada PD-1 and PD-L1 Monoclonal Antibodies Market Size Growth 2021-2026 ($ millions)
Figure 30. Mexico PD-1 and PD-L1 Monoclonal Antibodies Market Size Growth 2021-2026 ($ millions)
Figure 31. Brazil PD-1 and PD-L1 Monoclonal Antibodies Market Size Growth 2021-2026 ($ millions)
Figure 32. APAC PD-1 and PD-L1 Monoclonal Antibodies Market Size Market Share by Region in 2025
Figure 33. APAC PD-1 and PD-L1 Monoclonal Antibodies Market Size Market Share by Target (2021-2026)
Figure 34. APAC PD-1 and PD-L1 Monoclonal Antibodies Market Size Market Share by Application (2021-2026)
Figure 35. China PD-1 and PD-L1 Monoclonal Antibodies Market Size Growth 2021-2026 ($ millions)
Figure 36. Japan PD-1 and PD-L1 Monoclonal Antibodies Market Size Growth 2021-2026 ($ millions)
Figure 37. South Korea PD-1 and PD-L1 Monoclonal Antibodies Market Size Growth 2021-2026 ($ millions)
Figure 38. Southeast Asia PD-1 and PD-L1 Monoclonal Antibodies Market Size Growth 2021-2026 ($ millions)
Figure 39. India PD-1 and PD-L1 Monoclonal Antibodies Market Size Growth 2021-2026 ($ millions)
Figure 40. Australia PD-1 and PD-L1 Monoclonal Antibodies Market Size Growth 2021-2026 ($ millions)
Figure 41. Europe PD-1 and PD-L1 Monoclonal Antibodies Market Size Market Share by Country in 2025
Figure 42. Europe PD-1 and PD-L1 Monoclonal Antibodies Market Size Market Share by Target (2021-2026)
Figure 43. Europe PD-1 and PD-L1 Monoclonal Antibodies Market Size Market Share by Application (2021-2026)
Figure 44. Germany PD-1 and PD-L1 Monoclonal Antibodies Market Size Growth 2021-2026 ($ millions)
Figure 45. France PD-1 and PD-L1 Monoclonal Antibodies Market Size Growth 2021-2026 ($ millions)
Figure 46. UK PD-1 and PD-L1 Monoclonal Antibodies Market Size Growth 2021-2026 ($ millions)
Figure 47. Italy PD-1 and PD-L1 Monoclonal Antibodies Market Size Growth 2021-2026 ($ millions)
Figure 48. Russia PD-1 and PD-L1 Monoclonal Antibodies Market Size Growth 2021-2026 ($ millions)
Figure 49. Middle East & Africa PD-1 and PD-L1 Monoclonal Antibodies Market Size Market Share by Region (2021-2026)
Figure 50. Middle East & Africa PD-1 and PD-L1 Monoclonal Antibodies Market Size Market Share by Target (2021-2026)
Figure 51. Middle East & Africa PD-1 and PD-L1 Monoclonal Antibodies Market Size Market Share by Application (2021-2026)
Figure 52. Egypt PD-1 and PD-L1 Monoclonal Antibodies Market Size Growth 2021-2026 ($ millions)
Figure 53. South Africa PD-1 and PD-L1 Monoclonal Antibodies Market Size Growth 2021-2026 ($ millions)
Figure 54. Israel PD-1 and PD-L1 Monoclonal Antibodies Market Size Growth 2021-2026 ($ millions)
Figure 55. Turkey PD-1 and PD-L1 Monoclonal Antibodies Market Size Growth 2021-2026 ($ millions)
Figure 56. GCC Countries PD-1 and PD-L1 Monoclonal Antibodies Market Size Growth 2021-2026 ($ millions)
Figure 57. Americas PD-1 and PD-L1 Monoclonal Antibodies Market Size 2027-2032 ($ millions)
Figure 58. APAC PD-1 and PD-L1 Monoclonal Antibodies Market Size 2027-2032 ($ millions)
Figure 59. Europe PD-1 and PD-L1 Monoclonal Antibodies Market Size 2027-2032 ($ millions)
Figure 60. Middle East & Africa PD-1 and PD-L1 Monoclonal Antibodies Market Size 2027-2032 ($ millions)
Figure 61. United States PD-1 and PD-L1 Monoclonal Antibodies Market Size 2027-2032 ($ millions)
Figure 62. Canada PD-1 and PD-L1 Monoclonal Antibodies Market Size 2027-2032 ($ millions)
Figure 63. Mexico PD-1 and PD-L1 Monoclonal Antibodies Market Size 2027-2032 ($ millions)
Figure 64. Brazil PD-1 and PD-L1 Monoclonal Antibodies Market Size 2027-2032 ($ millions)
Figure 65. China PD-1 and PD-L1 Monoclonal Antibodies Market Size 2027-2032 ($ millions)
Figure 66. Japan PD-1 and PD-L1 Monoclonal Antibodies Market Size 2027-2032 ($ millions)
Figure 67. Korea PD-1 and PD-L1 Monoclonal Antibodies Market Size 2027-2032 ($ millions)
Figure 68. Southeast Asia PD-1 and PD-L1 Monoclonal Antibodies Market Size 2027-2032 ($ millions)
Figure 69. India PD-1 and PD-L1 Monoclonal Antibodies Market Size 2027-2032 ($ millions)
Figure 70. Australia PD-1 and PD-L1 Monoclonal Antibodies Market Size 2027-2032 ($ millions)
Figure 71. Germany PD-1 and PD-L1 Monoclonal Antibodies Market Size 2027-2032 ($ millions)
Figure 72. France PD-1 and PD-L1 Monoclonal Antibodies Market Size 2027-2032 ($ millions)
Figure 73. UK PD-1 and PD-L1 Monoclonal Antibodies Market Size 2027-2032 ($ millions)
Figure 74. Italy PD-1 and PD-L1 Monoclonal Antibodies Market Size 2027-2032 ($ millions)
Figure 75. Russia PD-1 and PD-L1 Monoclonal Antibodies Market Size 2027-2032 ($ millions)
Figure 76. Egypt PD-1 and PD-L1 Monoclonal Antibodies Market Size 2027-2032 ($ millions)
Figure 77. South Africa PD-1 and PD-L1 Monoclonal Antibodies Market Size 2027-2032 ($ millions)
Figure 78. Israel PD-1 and PD-L1 Monoclonal Antibodies Market Size 2027-2032 ($ millions)
Figure 79. Turkey PD-1 and PD-L1 Monoclonal Antibodies Market Size 2027-2032 ($ millions)
Figure 80. Global PD-1 and PD-L1 Monoclonal Antibodies Market Size Market Share Forecast by Target (2027-2032)
Figure 81. Global PD-1 and PD-L1 Monoclonal Antibodies Market Size Market Share Forecast by Application (2027-2032)
Figure 82. GCC Countries PD-1 and PD-L1 Monoclonal Antibodies Market Size 2027-2032 ($ millions)
Figure 1. PD-1 and PD-L1 Monoclonal Antibodies Report Years Considered
Figure 2. Research Objectives
Figure 3. Research Methodology
Figure 4. Research Process and Data Source
Figure 5. Global PD-1 and PD-L1 Monoclonal Antibodies Market Size Growth Rate (2021-2032) ($ millions)
Figure 6. PD-1 and PD-L1 Monoclonal Antibodies Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 7. PD-1 and PD-L1 Monoclonal Antibodies Sales Market Share by Country/Region (2025)
Figure 8. PD-1 and PD-L1 Monoclonal Antibodies Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 9. Global PD-1 and PD-L1 Monoclonal Antibodies Market Size Market Share by Target in 2025
Figure 10. Global PD-1 and PD-L1 Monoclonal Antibodies Market Size Market Share by Antibody Origin in 2025
Figure 11. Global PD-1 and PD-L1 Monoclonal Antibodies Market Size Market Share by Dosing Interval in 2025
Figure 12. PD-1 and PD-L1 Monoclonal Antibodies in Lung Cancer Treatment
Figure 13. Global PD-1 and PD-L1 Monoclonal Antibodies Market: Lung Cancer Treatment (2021-2026) & ($ millions)
Figure 14. PD-1 and PD-L1 Monoclonal Antibodies in Melanoma Treatment
Figure 15. Global PD-1 and PD-L1 Monoclonal Antibodies Market: Melanoma Treatment (2021-2026) & ($ millions)
Figure 16. PD-1 and PD-L1 Monoclonal Antibodies in Bowel Cancer Treatment
Figure 17. Global PD-1 and PD-L1 Monoclonal Antibodies Market: Bowel Cancer Treatment (2021-2026) & ($ millions)
Figure 18. PD-1 and PD-L1 Monoclonal Antibodies in Other
Figure 19. Global PD-1 and PD-L1 Monoclonal Antibodies Market: Other (2021-2026) & ($ millions)
Figure 20. Global PD-1 and PD-L1 Monoclonal Antibodies Market Size Market Share by Application in 2025
Figure 21. Global PD-1 and PD-L1 Monoclonal Antibodies Revenue Market Share by Player in 2025
Figure 22. Global PD-1 and PD-L1 Monoclonal Antibodies Market Size Market Share by Region (2021-2026)
Figure 23. Americas PD-1 and PD-L1 Monoclonal Antibodies Market Size 2021-2026 ($ millions)
Figure 24. APAC PD-1 and PD-L1 Monoclonal Antibodies Market Size 2021-2026 ($ millions)
Figure 25. Europe PD-1 and PD-L1 Monoclonal Antibodies Market Size 2021-2026 ($ millions)
Figure 26. Middle East & Africa PD-1 and PD-L1 Monoclonal Antibodies Market Size 2021-2026 ($ millions)
Figure 27. Americas PD-1 and PD-L1 Monoclonal Antibodies Value Market Share by Country in 2025
Figure 28. United States PD-1 and PD-L1 Monoclonal Antibodies Market Size Growth 2021-2026 ($ millions)
Figure 29. Canada PD-1 and PD-L1 Monoclonal Antibodies Market Size Growth 2021-2026 ($ millions)
Figure 30. Mexico PD-1 and PD-L1 Monoclonal Antibodies Market Size Growth 2021-2026 ($ millions)
Figure 31. Brazil PD-1 and PD-L1 Monoclonal Antibodies Market Size Growth 2021-2026 ($ millions)
Figure 32. APAC PD-1 and PD-L1 Monoclonal Antibodies Market Size Market Share by Region in 2025
Figure 33. APAC PD-1 and PD-L1 Monoclonal Antibodies Market Size Market Share by Target (2021-2026)
Figure 34. APAC PD-1 and PD-L1 Monoclonal Antibodies Market Size Market Share by Application (2021-2026)
Figure 35. China PD-1 and PD-L1 Monoclonal Antibodies Market Size Growth 2021-2026 ($ millions)
Figure 36. Japan PD-1 and PD-L1 Monoclonal Antibodies Market Size Growth 2021-2026 ($ millions)
Figure 37. South Korea PD-1 and PD-L1 Monoclonal Antibodies Market Size Growth 2021-2026 ($ millions)
Figure 38. Southeast Asia PD-1 and PD-L1 Monoclonal Antibodies Market Size Growth 2021-2026 ($ millions)
Figure 39. India PD-1 and PD-L1 Monoclonal Antibodies Market Size Growth 2021-2026 ($ millions)
Figure 40. Australia PD-1 and PD-L1 Monoclonal Antibodies Market Size Growth 2021-2026 ($ millions)
Figure 41. Europe PD-1 and PD-L1 Monoclonal Antibodies Market Size Market Share by Country in 2025
Figure 42. Europe PD-1 and PD-L1 Monoclonal Antibodies Market Size Market Share by Target (2021-2026)
Figure 43. Europe PD-1 and PD-L1 Monoclonal Antibodies Market Size Market Share by Application (2021-2026)
Figure 44. Germany PD-1 and PD-L1 Monoclonal Antibodies Market Size Growth 2021-2026 ($ millions)
Figure 45. France PD-1 and PD-L1 Monoclonal Antibodies Market Size Growth 2021-2026 ($ millions)
Figure 46. UK PD-1 and PD-L1 Monoclonal Antibodies Market Size Growth 2021-2026 ($ millions)
Figure 47. Italy PD-1 and PD-L1 Monoclonal Antibodies Market Size Growth 2021-2026 ($ millions)
Figure 48. Russia PD-1 and PD-L1 Monoclonal Antibodies Market Size Growth 2021-2026 ($ millions)
Figure 49. Middle East & Africa PD-1 and PD-L1 Monoclonal Antibodies Market Size Market Share by Region (2021-2026)
Figure 50. Middle East & Africa PD-1 and PD-L1 Monoclonal Antibodies Market Size Market Share by Target (2021-2026)
Figure 51. Middle East & Africa PD-1 and PD-L1 Monoclonal Antibodies Market Size Market Share by Application (2021-2026)
Figure 52. Egypt PD-1 and PD-L1 Monoclonal Antibodies Market Size Growth 2021-2026 ($ millions)
Figure 53. South Africa PD-1 and PD-L1 Monoclonal Antibodies Market Size Growth 2021-2026 ($ millions)
Figure 54. Israel PD-1 and PD-L1 Monoclonal Antibodies Market Size Growth 2021-2026 ($ millions)
Figure 55. Turkey PD-1 and PD-L1 Monoclonal Antibodies Market Size Growth 2021-2026 ($ millions)
Figure 56. GCC Countries PD-1 and PD-L1 Monoclonal Antibodies Market Size Growth 2021-2026 ($ millions)
Figure 57. Americas PD-1 and PD-L1 Monoclonal Antibodies Market Size 2027-2032 ($ millions)
Figure 58. APAC PD-1 and PD-L1 Monoclonal Antibodies Market Size 2027-2032 ($ millions)
Figure 59. Europe PD-1 and PD-L1 Monoclonal Antibodies Market Size 2027-2032 ($ millions)
Figure 60. Middle East & Africa PD-1 and PD-L1 Monoclonal Antibodies Market Size 2027-2032 ($ millions)
Figure 61. United States PD-1 and PD-L1 Monoclonal Antibodies Market Size 2027-2032 ($ millions)
Figure 62. Canada PD-1 and PD-L1 Monoclonal Antibodies Market Size 2027-2032 ($ millions)
Figure 63. Mexico PD-1 and PD-L1 Monoclonal Antibodies Market Size 2027-2032 ($ millions)
Figure 64. Brazil PD-1 and PD-L1 Monoclonal Antibodies Market Size 2027-2032 ($ millions)
Figure 65. China PD-1 and PD-L1 Monoclonal Antibodies Market Size 2027-2032 ($ millions)
Figure 66. Japan PD-1 and PD-L1 Monoclonal Antibodies Market Size 2027-2032 ($ millions)
Figure 67. Korea PD-1 and PD-L1 Monoclonal Antibodies Market Size 2027-2032 ($ millions)
Figure 68. Southeast Asia PD-1 and PD-L1 Monoclonal Antibodies Market Size 2027-2032 ($ millions)
Figure 69. India PD-1 and PD-L1 Monoclonal Antibodies Market Size 2027-2032 ($ millions)
Figure 70. Australia PD-1 and PD-L1 Monoclonal Antibodies Market Size 2027-2032 ($ millions)
Figure 71. Germany PD-1 and PD-L1 Monoclonal Antibodies Market Size 2027-2032 ($ millions)
Figure 72. France PD-1 and PD-L1 Monoclonal Antibodies Market Size 2027-2032 ($ millions)
Figure 73. UK PD-1 and PD-L1 Monoclonal Antibodies Market Size 2027-2032 ($ millions)
Figure 74. Italy PD-1 and PD-L1 Monoclonal Antibodies Market Size 2027-2032 ($ millions)
Figure 75. Russia PD-1 and PD-L1 Monoclonal Antibodies Market Size 2027-2032 ($ millions)
Figure 76. Egypt PD-1 and PD-L1 Monoclonal Antibodies Market Size 2027-2032 ($ millions)
Figure 77. South Africa PD-1 and PD-L1 Monoclonal Antibodies Market Size 2027-2032 ($ millions)
Figure 78. Israel PD-1 and PD-L1 Monoclonal Antibodies Market Size 2027-2032 ($ millions)
Figure 79. Turkey PD-1 and PD-L1 Monoclonal Antibodies Market Size 2027-2032 ($ millions)
Figure 80. Global PD-1 and PD-L1 Monoclonal Antibodies Market Size Market Share Forecast by Target (2027-2032)
Figure 81. Global PD-1 and PD-L1 Monoclonal Antibodies Market Size Market Share Forecast by Application (2027-2032)
Figure 82. GCC Countries PD-1 and PD-L1 Monoclonal Antibodies Market Size 2027-2032 ($ millions)
